https://www.selleckchem.com/products/OSI-930.html
Treatment of glioblastomas (GBM) using the Auger electron emitting compound [ I]5-Iodo-2'-deoxyuridine ([ I]I-UdR), combined with the thymidylate synthase inhibitor methotrexate (MTX) and concomitant chemotherapy with temozolomide (TMZ) has recently shown very promising therapeutic effects in vitro and in vivo in animals. The aim of the current study was to investigate if the therapeutic effects of this multimodal treatment strategy could be further increased by the thymidylate synthase inhibitor, 5-fluoro-2'-deoxyuridine (F-UdR), in co
Aimer
Commentaire
Partagez
